# VibeRounds — Full Case Analysis

**Case:** Thyroid swelling with pressure symptoms, suspected malignancy, with coexisting biochemical subclinical hyperthyroidism — Case 2, 20 June 2026 (submitted as a brief clinical vignette, no external case link)

> **Source note:** No case link was provided. This case was submitted directly as a short prospective clinical narrative. Per the Master Protocol's quality gate, this has been confirmed sufficient to support more than 8 usable VibeRounds prompts and has been classified as a single-system (thyroid) case with secondary systemic effects, rather than a complex multi-system case — hence the 8-prompt minimum (not 15) was applied at Stage 2.

---

## Workflow Description

**Stage 1 (Case Ingestion)** extracted all available structured clinical data from the vignette and explicitly flagged unrecorded fields rather than inferring them, in line with protocol requirements. **Stage 2 (Prompt Mapping)** systematically reviewed all 20 VibeRounds modules against this case's features — diagnostic uncertainty around malignancy, a functional thyroid abnormality coexisting with a structural lesion, an imminent procedure under altered physiology, and patient-education needs — and mapped 12 directly applicable clinical prompts plus the structural requirement for Stage 6. **Stage 3 (Prompt Ranking)** scored each mapped prompt 1–10 on clinical importance specific to this patient, identifying 7 prompts in the 8–10 "high-value" band. **Stage 4 (High-Value Prompt Execution)** answered each of those 7 prompts in full clinical depth, applying causal-network mapping, adversarial reasoning, and mechanism-based analysis as specified by their respective modules. **Stage 5 (Insight Synthesis)** distilled the highest-importance, case-specific learning points from all analysis into a ranked top-10 list. **Stage 6 (CARE Report + Advocate Debrief)**, presented in File 3, produces a structured case report and an advocate-journey framework — explicitly marked as *prospective/projected* given that this case's biopsy, full work-up, and outcome are not yet completed.

---

## Section 1 — Full Case Summary Table

| Field | Extracted Data |
|---|---|
| Demographics (age, sex, occupation, background) | `[NOT DOCUMENTED]` |
| Chief complaint | Recent thyroid swelling with pressure symptoms |
| Background history | Loss of appetite × 2 months (longer-standing than the swelling); thyroid swelling is more recent in onset |
| Symptom timeline | Anorexia: onset ~2 months ago, ongoing. Thyroid swelling: more recent onset, exact duration `[NOT DOCUMENTED]`; pressure symptoms present but unspecified in nature |
| Medications | `[NOT DOCUMENTED]` |
| Examination findings | Mild lid lag, tremor, tachycardia documented. Thyroid local exam (size, consistency, mobility, lymphadenopathy, retrosternal extension, tracheal deviation) and exact vitals `[NOT DOCUMENTED]` |
| Investigations | "Biochemical subclinical hyperthyroidism" stated (implies suppressed TSH with normal fT4/fT3); actual TSH/fT4/fT3/TRAb values, thyroid USG, FNAC, calcitonin all `[NOT DOCUMENTED]` |
| Procedures performed | None yet; FNAC and excision biopsy **planned**, not yet performed |
| Working diagnoses | Suspected thyroid malignancy; biochemical subclinical hyperthyroidism |
| Management given | `[NOT DOCUMENTED]` — no anti-thyroid drugs, beta-blockers, or other treatment recorded as started |
| Outcome | Pending — case is prospective/in-progress |
| Investigations indicated but not yet documented | Thyroid USG with TI-RADS-type characterisation, TSH/fT4/fT3, TRAb/TSI, thyroid scintigraphy, neck CT/MRI (if retrosternal extension suspected), indirect laryngoscopy, serum calcitonin (if medullary carcinoma suspected), ECG |
| Patient/advocate narrative | `[NOT DOCUMENTED]` |

---

## Section 2 — Prompt Mapping Table (Stage 2)

| # | Module | Step | Prompt Purpose | Patient-Context Trigger |
|---|---|---|---|---|
| 1 | M1 — Socratic Clinical Reasoning | 1.4 Mid-Session Reasoning Checkpoint | Score diagnostic logic on the malignancy-vs-functional-disease split | Genuine diagnostic uncertainty present |
| 2 | M1 — Socratic Clinical Reasoning | 1.8 Missed Diagnosis Debrief | Identify what could be missed by anchoring on "malignancy" | Anchoring risk: anorexia + swelling pulls toward malignancy, away from thyrotoxicosis as anorexia driver |
| 3 | M9 — N-of-1 Research Protocol | Case framing | Coexistence of subclinical hyperthyroidism + suspected malignant nodule is an atypical, teachable combination | Complex, unusual combination suitable for structured write-up |
| 4 | M11 — Patient Education Query Intelligence | Plain-language briefing | Patient/family will need plain-language explanation of FNAC, biopsy, and "subclinical" hyperthyroidism | Procedure planned; diagnosis-in-progress anxiety |
| 5 | M12 — Differential Diagnosis Deepdive | Devil's Advocate Mode | Stress-test "suspected malignancy" before tissue confirmation | Working diagnosis formed but not yet confirmed — explicit anchoring risk |
| 6 | M14 — Resource-Constrained Reasoning | Missing-investigation reasoning | TSH/fT4/fT3 values, USG, TRAb not documented | Investigations seemingly unavailable/undocumented |
| 7 | M15 — Illness Script Acquisition | Script-mismatch identification | Anorexia + biochemical thyrotoxicosis is a script mismatch | Atypical presentation — script conflict explicitly present |
| 8 | M16 — Basic Science Integration | Mechanism mapping | How one nodule can cause both compressive and biochemical findings | Mechanism-to-diagnosis link central to this case |
| 9 | M17 — Semantic Qualifiers | Problem representation refinement | Sharpening "swelling" and "pressure symptoms" into precise qualifiers | Vague terms present; representation needs sharpening |
| 10 | M18 — Causal Network Reasoning | Conditional reweighting | Hyperthyroid state changes weight of malignancy risk and biopsy safety | Multiple findings interact conditionally |
| 11 | M19 — Community & Social Medicine | Determinants context | Diagnostic delay, iodine status, access to USG/FNAC | Social/health-system determinants plausibly relevant |
| 12 | M4 — Ward Round Preparation | Pre-procedure safety prep | Pre-biopsy and pre-surgery work-up and safety checklist | Procedure (FNAC, excision biopsy) imminent |
| 13 | M2/M3 — Advocate Documentation/Monitoring | Structural requirement | Required scaffold for Stage 6 deliverable | No advocate narrative present in source; framework needed for File 3 |

*M13 (Polypharmacy) and M20 (Recognition-Primed Decision) were reviewed and excluded — no 5+ medications or drug-disease conflicts present, and no acute/time-critical deterioration moment exists in this case.*

---

## Section 3 — Ranked Prompt Table (Stage 3)

| Rank | Score | Prompt | Justification |
|---|---|---|---|
| 1 | 10 | M18 — Causal Network Reasoning (hyperthyroid state × malignancy risk × biopsy safety) | Directly determines next clinical action: biopsy timing, interpretation of cytology, and procedural sequencing. |
| 2 | 10 | M17 — Semantic Qualifiers (sharpening "swelling" + "pressure symptoms") | All downstream work-up (USG, FNAC technique, urgency) depends on precisely defining the presenting problem. |
| 3 | 9 | M15 — Illness Script Acquisition (anorexia + thyrotoxicosis script mismatch) | Anorexia is atypical for thyrotoxicosis; a real script clash requiring conscious resolution. |
| 4 | 9 | M12 — Differential Diagnosis Deepdive (Devil's Advocate on "suspected malignancy") | "Suspected malignancy" already adopted pre-tissue-diagnosis; high anchoring risk. |
| 5 | 9 | M16 — Basic Science Integration (mechanism of compressive + biochemical findings) | Explains whether one lesion or two separate processes are responsible — directly informs work-up. |
| 6 | 8 | M4 — Ward Round / Pre-Procedure Preparation | FNAC/excision biopsy imminent; thyroid storm risk and airway risk are directly action-changing. |
| 7 | 8 | M11 — Patient Education Query Intelligence | Significant patient anxiety; correct framing affects informed consent quality. |
| 8 | 7 | M14 — Resource-Constrained Reasoning | Meaningful context on documentation/investigation gaps; not directly management-altering. |
| 9 | 6 | M9 — N-of-1 framing | Useful for teaching structure; doesn't change immediate management. |
| 10 | 6 | M19 — Community & Social Medicine | Relevant background factor; secondary to immediate diagnostic-safety questions. |
| 11 | 5 | M1 — Mid-Session Reasoning Checkpoint | Pedagogical scaffolding value; not management-altering. |
| 12 | 4 | M1 — Missed Diagnosis Debrief | Reflective/educational; substantial overlap with the higher-scored M12 entry. |

**7 prompts scored 8–10**, all answered in full in Section 4 below.

---

## Section 4 — High-Value Prompt Answers (Stage 4)

### Prompt: Causal Network Reasoning — Hyperthyroid State × Malignancy Risk × Biopsy Safety
**Score: 10 | Module 18**

The three core findings in this case do not sit independently — each one conditionally reweights the clinical significance of the others, and mapping that interaction changes what happens next.

**Node A: Biochemical subclinical hyperthyroidism** (suppressed TSH, normal fT4/fT3 — inferred from the term used) → **Node B: Thyroid swelling with suspected malignancy** → **Node C: Adrenergic findings** (lid lag, tremor, tachycardia).

The conditional logic runs as follows. If the swelling were a single autonomously functioning nodule (toxic adenoma), Node A and Node B become causally linked rather than coincidental — the nodule itself is producing the biochemical picture. This matters enormously for Node B's malignancy risk: hyperfunctioning ("hot") thyroid nodules carry a substantially lower probability of malignancy than non-functioning ("cold") nodules, because autonomously functioning cells are differentiated enough to retain hormone synthesis machinery, a feature malignant transformation often disrupts. So the presence of biochemical hyperthyroidism, if traceable to the palpable swelling itself, should *lower* the prior probability of malignancy at that specific site — the opposite of how "thyroid swelling + suspected malignancy" reads in isolation. This is precisely why thyroid scintigraphy before or alongside FNAC is high-value here: if the swelling is "hot" on scan, FNAC is often deprioritised for that nodule (hot nodules are rarely biopsied, since cytology in a hyperfunctioning nodule has a higher false-positive atypia rate and the lesion is usually benign). If the swelling is "cold" while the patient is biochemically thyrotoxic, that argues *against* a single unifying lesion — raising suspicion of a separate cause for thyrotoxicosis (early Graves', a toxic nodule elsewhere in the gland) occurring alongside an unrelated, genuinely suspicious cold nodule. These are clinically very different scenarios requiring different next steps, and the case as described does not yet distinguish between them.

Node C (tremor, tachycardia, lid lag) reweights procedural safety, not diagnosis. Even "subclinical" hyperthyroidism with clinical adrenergic signs raises the question of whether this patient is adequately prepared for FNAC and especially for excision biopsy. FNAC itself is low-risk and generally safe to proceed with even in active thyrotoxicosis. Excision biopsy (likely meaning diagnostic lobectomy or open biopsy) is different — surgery on a thyrotoxic gland carries a recognised risk of intraoperative or postoperative thyroid storm, and tachycardia plus tremor are exactly the early clinical markers used to flag inadequate control. This means Node C should *gate the timing* of Node B's surgical resolution: the causal chain runs adrenergic signs → control thyroid function first → then proceed to excision, rather than treating biopsy planning and thyroid-function correction as parallel, unrelated tracks.

**Net effect:** the malignancy-risk estimate cannot be finalised without imaging/scan correlation of the biochemical and structural findings, and procedural sequencing (FNAC now vs. defer; excision biopsy now vs. after beta-blockade/control) is directly gated by Node C. Treating these three findings as independent — "malignant until proven otherwise" plus "thyrotoxic, incidentally" — is the central reasoning trap this case sets up.

---

### Prompt: Semantic Qualifiers & Problem Representation
**Score: 10 | Module 17**

The presenting complaint as given — "thyroid swelling with pressure symptoms" — is a low-information problem representation that needs sharpening into qualifier pairs before any meaningful work-up planning is possible.

| Vague term used | Semantic qualifiers needed | Why it matters |
|---|---|---|
| "Thyroid swelling" | Diffuse vs. nodular (solitary vs. multinodular); unilateral vs. bilateral; size; consistency (firm/hard/rubbery); mobility with swallowing; fixity to underlying structures | Diffuse symmetric goitre with thyrotoxicosis suggests Graves'; a firm, fixed, irregular solitary nodule suggests malignancy; multinodular goitre with a dominant hyperfunctioning area suggests toxic MNG. Each maps to a different pre-biopsy pathway. |
| "Recent" onset | Acute (days–weeks) vs. subacute (weeks–months) vs. chronic with recent change | A long-standing goitre with recent rapid growth is itself a malignancy red flag; a genuinely new swelling is a different differential (including subacute thyroiditis, which can also produce transient biochemical thyrotoxicosis and tenderness). |
| "Pressure symptoms" | Dysphagia vs. dyspnoea/stridor vs. dysphonia/hoarseness vs. local discomfort only | Dysphonia raises concern for recurrent laryngeal nerve involvement — a hard malignancy sign requiring indirect laryngoscopy before any neck surgery. Stridor/dyspnoea raises airway/tracheal compression urgency, changing imaging priority and anaesthetic risk discussion. |
| "Subclinical hyperthyroidism" | Grade 1 (mildly suppressed, detectable TSH) vs. Grade 2 (fully suppressed, undetectable TSH) | Grade 2 carries materially higher risk of atrial fibrillation and bone loss, and is managed more assertively than Grade 1. |
| "Loss of appetite" | Genuine anorexia vs. early satiety from compressive oesophageal effect vs. odynophagia | These have completely different mechanisms — true anorexia points toward a systemic/malignant or hypermetabolic process, while early satiety/dysphagia from local compression is purely structural. |

Until these qualifiers are populated from a proper history and examination, the problem representation remains "a swelling with vague pressure and an appetite issue" — not enough to commit a differential to writing, let alone justify "suspected malignancy" as the leading framing over alternatives.

---

### Prompt: Illness Script Acquisition — The Anorexia/Thyrotoxicosis Script Mismatch
**Score: 9 | Module 15**

This case contains a genuine illness-script conflict that a clinician pattern-matching too quickly could miss. The classic illness script for hyperthyroidism (Graves', toxic nodule, toxic MNG) includes **increased** appetite with paradoxical weight loss, due to the hypermetabolic state outpacing caloric intake — patients typically report eating more, not less. Anorexia (reduced appetite, not just weight loss) is **not** part of the standard thyrotoxicosis script. It is, however, a recognised script element for thyroid malignancy with systemic burden, for apathetic/elderly-pattern thyrotoxicosis (a recognised atypical variant where adrenergic features are blunted and depression/anorexia/weight loss dominate, more common in older patients), and for unrelated overlapping pathology (a separate malignancy, depression, or hypothyroid component coexisting with a hyperfunctioning nodule in a multinodular gland).

The risk here is **script substitution error**: a clinician who hears "thyroid swelling + hyperthyroid labs" may activate the standard Graves'/toxic-nodule script wholesale and file the anorexia under "well, thyrotoxicosis causes weight loss" without registering that *appetite direction* is the wrong sign for that script. The correct response is to flag the anorexia as a script-discordant feature that should actively raise — not lower — suspicion for malignancy or for an atypical/apathetic thyrotoxicosis presentation, and to specifically ask the patient about appetite change direction (not just weight change), screen for depression, and consider age as a modifier. This single qualifier — appetite increased vs. decreased — is one of the highest-yield, lowest-cost discriminators available in this case and should be explicitly elicited and documented if it has not been already.

---

### Prompt: Differential Diagnosis Deepdive — Devil's Advocate on "Suspected Malignancy"
**Score: 9 | Module 12**

"Suspected malignancy" has already been adopted as the working frame before any tissue diagnosis exists. Applying adversarial pressure to that label:

**The case against malignancy being the primary driver:** Biochemical hyperthyroidism is present and could fully explain the systemic symptom (weight/appetite change is well-documented in thyrotoxicosis, even if appetite-decrease specifically is atypical; anxiety and gut hypermotility from thyrotoxicosis can also blunt appetite in some patients). The "swelling" could represent a benign toxic adenoma or multinodular goitre — both common, both capable of producing compressive symptoms purely from bulk, with no malignant component at all. Pressure symptoms scale with size regardless of histology; a large benign colloid nodule can compress the trachea/oesophagus just as effectively as a malignant one. Lid lag, tremor, and tachycardia are pure adrenergic/thyrotoxic signs and contribute zero diagnostic weight toward malignancy — a clinician should be careful not to let "more findings" inflate confidence in "more dangerous diagnosis" when those findings belong to a separate causal pathway.

**The case for malignancy remaining on the differential:** Recent, apparently new-onset swelling (vs. long-standing) is a recognised red flag. Anorexia as an isolated, true-appetite-reduction symptom (if confirmed, per the M15 analysis above) is somewhat atypical for benign thyroid disease and warrants continued malignancy concern. Without examination details, hard malignancy signs (fixity, hardness, cervical lymphadenopathy, vocal cord palsy) cannot be excluded — their absence from the vignette is a documentation gap, not evidence against malignancy.

**Verdict of the adversarial pass:** the case for malignancy is currently asserted, not yet earned by the data presented. The biochemical thyrotoxicosis is doing no diagnostic work toward malignancy and should not be allowed to anchor the clinician further into that frame by association. FNAC remains the correct next step to settle this — the adversarial value here is ensuring the clinician proceeds to FNAC with genuine equipoise rather than treating it as confirmatory paperwork for a diagnosis already assumed.

---

### Prompt: Basic Science Integration — Mechanism Linking Mass Effect and Thyrotoxicosis
**Score: 9 | Module 16**

The mechanistic question this case poses is: can one thyroid lesion plausibly cause both a palpable, pressure-symptom-producing mass **and** biochemical hyperthyroidism, and if so, through what pathway?

A **toxic adenoma** arises from a somatic activating mutation in the TSH receptor (or downstream Gsα/cAMP pathway) within a single follicular cell clone, causing that clone to proliferate and secrete thyroid hormone autonomously, independent of pituitary TSH drive. As the clone grows, it increases hormone output (producing the biochemical thyrotoxicosis, with TSH suppressed by negative feedback) and increases physically in size (producing the compressive symptoms) simultaneously. This is the single mechanism that most parsimoniously explains both findings as causally linked rather than coincidental — exactly the structure the causal-network analysis above flags as needing confirmation via scintigraphy.

The alternative mechanistic pathway — **Graves' disease** (TSH-receptor stimulating autoantibodies driving diffuse glandular hyperplasia and hormone overproduction) — also causes both diffuse goitre and thyrotoxicosis, but through autoimmune stimulation rather than a single autonomous clone. Mechanistically this would predict diffuse rather than nodular enlargement, and would correlate with TRAb/TSI positivity and possibly orbital/dermal extrathyroidal features (worth distinguishing explicitly from the already-noted lid lag, which is a sympathetic-overactivity sign common to *any* cause of thyrotoxicosis, not Graves'-specific — true Graves' orbitopathy involves proptosis/periorbital changes).

A third mechanistic possibility — and the one that would **break** the unifying narrative — is that the swelling represents a non-functioning malignant nodule arising in a gland that has, separately, developed autonomous hyperfunction elsewhere. Thyroid carcinomas, especially differentiated ones, typically do **not** secrete functional hormone autonomously in a TSH-independent way and are usually "cold" on scintigraphy — meaning if the palpable swelling itself is malignant, it is mechanistically unlikely to be the source of the biochemical thyrotoxicosis, and a second, separate functional abnormality should be sought elsewhere in the gland. This branching is exactly why imaging that localises function (scintigraphy) and structure (USG) to the *same or different* areas of the gland is the pivotal next investigation.

---

### Prompt: Ward Round / Pre-Procedure Preparation
**Score: 8 | Module 4**

**Before FNAC:** FNAC is generally safe to proceed with regardless of thyroid function status and should not be delayed by the biochemical hyperthyroidism — a clinician might reflexively want to "correct the thyroid first," but this is not required for FNAC specifically. Priorities before FNAC: complete thyroid USG with nodule characterisation (size, margins, echogenicity, microcalcifications, taller-than-wide shape, vascularity) to guide which nodule(s) to sample if multiple are present; baseline TSH/fT4/fT3/TRAb to characterise the thyrotoxicosis grade and likely cause; coagulation screen; and indirect laryngoscopy to document baseline vocal cord function — both a malignancy red-flag check and a medicolegal/clinical baseline before any subsequent surgery.

**Before excision biopsy specifically:** this is where the adrenergic signs become directly action-relevant. Surgery under inadequately controlled thyrotoxicosis carries a recognised risk of perioperative thyroid storm, triggered by the surgical stress response in a hyperfunctioning gland. The standard approach is to achieve a euthyroid or at least beta-blockade-controlled state before elective thyroid surgery — typically with a non-selective beta-blocker (e.g., propranolol) to control adrenergic symptoms and blunt peripheral T4-to-T3 conversion, even in "subclinical" disease, if clinical signs (as here) are present. Heart rate and tremor should be reassessed and likely treated with beta-blockade prior to the excision biopsy proceeding, not after.

---

### Prompt: Patient Education Query Intelligence
**Score: 8 | Module 11**

The patient is in a genuinely anxiety-provoking position: an unexplained 2-month appetite/weight problem, a new neck swelling, the word "malignancy" already in play, and two procedures pending. The patient-education needs cluster around three plain-language points.

First, explaining **why a needle test happens before any decision about cancer** — FNAC is a sampling test, not a treatment, and many thyroid nodules sampled this way turn out to be benign; many patients hear "biopsy" and assume cancer is already strongly suspected medically, rather than understanding it as the standard evaluation step for any new thyroid nodule meeting certain criteria.

Second, explaining the **two separate problems in plain terms** — that there appear to be two things happening (a lump being checked for its nature, and the thyroid gland producing slightly too much hormone, causing the racing heart and shaky hands), investigated and managed somewhat separately, so the patient doesn't conflate "my heart is racing" with "the cancer has spread" — a very common and distressing misunderstanding in exactly this combination.

Third, explaining **why the heart-rate/tremor symptoms need treating before the bigger procedure** — giving the patient a concrete, reassuring reason ("we want your body in the calmest possible state before that operation, for your safety") rather than leaving a gap where any beta-blockade run-in period might be misread as a sign of worsening disease.

---

## Footer

*This is File 2 of a three-file VibeRounds output. See companion files:*
- *File 1 — `VibeRounds-TopInsights-AdultM-or-F-Thyroid-Swelling-SubclinicalHyperthyroidism.md` (standalone top-10 insight summary)*
- *File 3 — `VibeRounds-CARE-AdvocateDebrief-AdultM-or-F-Thyroid-Swelling-SubclinicalHyperthyroidism.md` (CARE case report and advocate debrief)*

**VibeRounds Disclaimer:** This output is educational. It is not a clinical decision support system, not a diagnostic oracle, and not a substitute for licensed clinical judgment. Independent clinical verification is required before any action is taken on this content. This case was analysed from a brief vignette with several fields explicitly marked `[NOT DOCUMENTED]`; conclusions are provisional pending full examination and investigation data.
